TrialCancer2010

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.

Eric Jonasch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.